We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc | NASDAQ:RARE | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.45 | -1.04% | 42.75 | 41.00 | 46.89 | 46.005 | 42.675 | 44.88 | 1,143,019 | 01:00:00 |
From May 2021 to May 2024
By Colin Kellaher
Ultragenyx Pharmaceutical Inc. on Tuesday said the U.S. Food and Drug Administration and the European Commission granted orphan-drug designation to UX053 for the treatment of glycogen storage disease type III.
The Novato, Calif., biopharmaceutical company said there are currently no approved treatment options for the rare metabolic disease that results in glycogen accumulation in the liver and muscle and affects more than 10,000 patients in the developed world.
The FDA's orphan-drug program gives special status to drugs and biologics for diseases and disorders that affect fewer than 200,000 people in the U.S. and provides for an extended marketing exclusivity period against competition.
Ultragenyx said it expects to begin enrollment in a Phase 1/2 clinical trial evaluating the safety, tolerability, and efficacy of UX053 in adults in the second half of 2021.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 27, 2021 08:34 ET (12:34 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Ultragenyx Pharmaceutical Chart |
1 Month Ultragenyx Pharmaceutical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
